Biotechnology

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health

SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northw...

2025-10-28 17:00 1355

Samsung Biologics reports third quarter 2025 financial results

* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...

2025-10-28 14:50 943

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) p...

2025-10-27 19:15 1670

MINISH Technology Has Successfully Concluded Its First U.S. MINISH Veneers Course, Certifying 22 Dentists

SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Health-tech company MINISH Technology Inc. announced on the 27th that 22 dentists completed its 15th MINISH Course, the first session held for local practitioners inthe United States.

2025-10-27 14:58 901

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of pa...

2025-10-25 15:00 2378

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...

2025-10-24 16:40 854

HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity

FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...

2025-10-24 07:30 1264

METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has...

2025-10-23 21:21 1152

HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology

* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. * Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Hanch...

2025-10-23 19:00 1154

MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring

SÃO PAULO, Oct. 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies to drive innovation in the life sciences, has entered into a strategic partnership with Eva Holding Group, a Brazilian group operating in genomics applied to hum...

2025-10-23 11:30 1031

SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging

LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company fromTaiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which w...

2025-10-23 00:00 1260

Visionary Holdings Launches Toronto-Based Joint Venture to Drive Global Commercialization of Innovative Stem Cell Therapy for Diabetes Remission, Targeting a $150 Billion Market Opportunity

TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike")...

2025-10-22 21:30 2555

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that theBlood published the latest result...

2025-10-22 19:39 1179

LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient

SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks...

2025-10-22 14:28 962

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku,Tokyo). T...

2025-10-22 14:00 829

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...

2025-10-22 08:30 909

HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101

TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...

2025-10-21 19:00 978

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...

2025-10-21 10:49 946

SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform

SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...

2025-10-21 09:20 1097

Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London

PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine....

2025-10-20 19:43 842
1234567 ... 154